| | 1012054-59-9 Basic information More.. |
| Product Name: | CUDC-101 | | Synonyms: | CUDC101;CUDC-101;7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide;HeptanaMide, 7-[[4-[(3-ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxy-;7-[[4-[(3-Ethynylphenyl)aMino]-7-Methoxy-6-quinazolinyl]oxy]-N-hydroxyheptanaMide;7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide CUDC-101;7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide;CUDC-101, >=98% | | CAS: | 1012054-59-9 | | MF: | C24H26N4O4 | | MW: | 434.49 | | EINECS: | | | Mol File: | 1012054-59-9.mol |  |
Use
CUDC-101 is a potent multi-acting HDAC (histone deacetylase), EGFR (epidermal growth factor receptor), and HER2 ( human epidermal growth factor receptor 2) inhibitor for the treatment of cancer.
- CUDC-101
-
- US $43.00-126.00 / mg
- 2024-11-19
- CAS:1012054-59-9
- Min. Order:
- Purity: 99.12%
- Supply Ability: 10g
|
|
1012054-59-9
Recommend Suppliers |
|